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Abstract 
We report results of our study of approved drugs as potential treatments for COVID-19, based on 
the application of various bioinformatics predictive methods. The drugs studied include 
hydroxychloroquine, Ivermectin, Remdesivir and α-difluoromethylornithine (DMFO). Our results 
indicate that these small drug molecules selectively bind to kinetically active and residues 
adjoining them on the surface and inside protein, and that some prefer hydrophobic over other 
active sites. Our approach is not restricted to viruses and can facilitate rational drug design, as 
well as improve our understanding of molecular interactions, in general. 
 
Introduction 
 
The Coronaviridae positive stranded RNA virus family includes a substantial number of members, 
many of whom are known to cause a broad range of illnesses from common cold to sever 
diseases like Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome 
(MERS), etc. [1, 2]. The latest worldwide rapidly spreading disease, COVID-19, is caused by a 
new member of this virus family, SARS-COV-2. The disease originally emerged in China in 
December 2019 with most common symptoms being fever and cough, as well as shortness of 
breath, sore throat, headache, muscles ache, nausea, and diarrhea [1]. In some cases initial 
symptoms also involve a still unexplained loss of smell and taste [3]. The SARS-COV-2 virus 
spreads by direct contact, from person to person and can severely affect patients with immune 
systems weakened by pre-existing conditions, such as hypertension, diabetes mellitus or 
cardiovascular diseases [4]. The virus has lower fatality rate than SARS and MERS, but spreads 
more easily due to high binding affinity between the virus spike glycoprotein (S) and the host 
receptor [5-8], making it, potentially, more deadly. The virus is therefore a primary cause or 
initiator of a significant number of deaths all over the world. It is also directly affecting global 
economy, with significant decline in gross national products worldwide and unemployment rates 
reaching levels not encountered since the Great depression. 
 
As this manuscript is being prepared there are several efforts and clinical trials underway to 
develop a vaccine and evaluate potential drugs for the COVID-19, but such investigations usually 
take months or even years to yield a successful treatment. Drug repurposing, on the other hand, 
may offer an immediate solution, because it considers already approved compounds as potential 
treatments for COVID-19. There are two paths toward a viral treatment. One path directly attacks 
the virus and interrupts its replication machinery [9] or its ability to attack host cells. However, 
infectious diseases of viral or bacterial origin have been notoriously difficult to treat directly due 
to often rapid emergence of new strains with acquired resistance to existing drugs. The second 
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path should therefore aim to block the host-viral interactions on the host side due to difficulties 
single point viral mutations should have in recovering the loos of human factors [10]. A recent 
study of human-virus protein-protein interactions detected 332 high-confidence SARS-CoV-2-
human protein-protein interactions (PPIs) [11]. The study showed that 40% of SARS-CoV-2 
proteins interact with endomembrane compartments or vesicle trafficking pathways, and that viral 
proteins also interact with multiple innate immune pathways, the host translation machinery, 
bromodomain proteins, enzymes involved in ubiquitination regulation, and Cullin ubiquitin ligase 
complex. Importantly, the study showed that the SARS-COV-2 human PPI map is very similar to 
the interaction maps of West Nile Virus (WNV) and Mycobacterium tuberculosis (Mtb). Among the 
human proteins involved in interactions with viral proteins, the study detected 66 druggable 
human (host) proteins targeted by 69 compounds (29 FDA-approved drugs, 12 drugs in clinical 
trials, and 28 preclinical compounds). It identified two groups of compounds with noticeable 
antiviral activity: inhibitors of mRNA translation/protein biogenesis (zotatifin, ternatin-4, PS3061, 
and plitidepsin), and predicted regulators of the Sigma1 and Sigma2 receptors (haloperidol, PB28, 
PD-144418, hydroxychloroquine, clemastine, cloperastine, progesterone, and the clinical 
molecule siramesine). The first group of compounds directly affects the viral cap-dependent 
mRNA translation because coronaviruses use the host translation machinery for their own mRNA 
translation. The compounds affecting the second group of proteins are approved and long 
established human therapeutics [11].  
 
As much as they are informative, screening associative studies as the one described above [11] 
rarely offer detailed insights into mechanisms of molecular interactions, whereas structural studies 
[5-8, 12] give snapshots into residue and atom level physical interactions between molecules, but 
cannot offer general principles of molecular interactions.  
 
To facilitate drug screening we undertook a comparative study of binding modes of various 
candidate drugs to viral and human proteins. We use those results to predict binging efficiency 
between the drugs and viral proteins. The drugs we have studied so far include 
(hydroxyl)chloroquine, Ivermectin, Remdesivir (and sofosbuvir), and α-difluoromethylornithine 
(DMFO) (see Table S1 in Supplementary material). Mass media, internet and even professional 
publications are currently immersed in controversial debates over the effectiveness, or lack of it, 
of some of those drug for the treatment of COVID-19. We avoid getting involved in such 
discussions and only report our research findings based on the existing bioinformatics predictive 
methods and tools [13, 14] and the methods which we have developed [15]. 
 
Chloroquine [16] and its less toxic derivative hydroxychloroquine [17] are drugs used to 
prevent and treat acute attacks of malaria. They are also used to treat discoid or systemic lupus 
erythematosus and rheumatoid arthritis in patients whose symptoms have not improved with other 
treatments. These drugs are subject of a number of clinical trials worldwide as potential treatment 
for Covid-19 [18, 19]. Interestingly, the above mentioned study [11] showed that PB28 was ~20 
times more potent viral inhibitor than hydroxychloroquine. 
 
Ivermectin is a medication used to treat many various types of parasite infestations [20]. They 
include, but not limited to, head lice, scabies, river blindness (onchocerciasis), strongyloidiasis, 
trichuriasis, ascariasis, and lymphatic filariasis. Depending on the kind of treatment, it is taken by 
mouth or applied to the skin for external infestations. Ivermectin molecular structure is rather 
complex and made of a set of macrocyclic lactone isomers. Ivermectin binds to glutamate-gated 
chloride channels and increases the permeability of chloride ions. The drug was shown to inhibit 
the replication of SARS-COV-2 in vitro [21] and is currently the subject of clinical trials as a 
potential COVID-19 treatment [22].  
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Remdesivir is a nucleoside analog RNA-dependent RNA Polymerase (RdRp) inhibitor initially 
developed to treat Ebola and Marburg virus diseases [9, 23]. The drug decreases the viral RNA 
production by affecting the function of RdRp and proofreading by viral exoribonuclease (ExoN). 
Remdesivir is a subject of clinical trials as a potential COVID-19 treatment [24], as it was shown 
to reduce the lung viral load and improve pulmonary function with SARS infection [9].   
 
α-difluoromethylornithine (DMFO), is a medication primary used to treat African 
trypanosomiasis (sleeping sickness) and excessive facial hair in women [25].  Specifically, it is 
used for the second stage of sleeping sickness caused by T. b. gambiense and may be used with 
nifurtimox [26]. It is used by injection or applied to the skin. The drug prevents binding of the 
natural product ornithine to the active site of ornithine decarboxylase. We did not find any record 
of this drug ever being tried, so far, for COVID-19. However, since it is a halogenated organic 
molecule with somehow similar active sites as chloroquine we decided to study it towards 
treatment of COVID-19. 
 
 
Results 
 
The analysis of chloroquine binding patterns to human lysosomal protein saposin B (pdb id 4v2o) 
and plasmodium falciparum lactate dehydrogenase (pdb id 1cet) shown in Figure 1. reveals that 
chloroquine binds to kinetically active sites recognized by the SAGNM algorithm which are mostly 
hydrophobic. Other active sites although exposed to solvent are not binding targets. The analysis 
of chloroquine’s nondiscriminatory binding to human and parasitic proteins may offer an 
explanation of its efficiency against parasitic infections as well offer a glimpse into its toxicity. It 
suggests that chloroquine’s binding to Covid-19 proteins will follow the same patterns of 
attachment to both hydrophobic and kinetically active residues.   
 
The drug Ivermectin binds glutamate-gated chloride channels and thus increases their 
permeability to chloride ions. We analyzed the Ivermectin’s binding to the human glycine receptor 
alpha-3 (pdb id 5vd). This structure has, besides Ivermectin, also glycine and the potentiator AM-
3607 (7c6) bound to the glycine receptor. The receptor is a pentamer, so we only analyzed the 
binding to its chain A. The analysis shown in Figure 2 reveals that all three compounds bind to 
kinetically active and adjoining residues (see [15]), some of which are highly hydrophobic. With 
Ivermectin almost all the binding residues are hydrophobic. That means that this drug well seek 
similar sites on the surface of Covid-19 proteins. 
 
We used the recently cryo-EM determined structure (pdb id 7bv2) of SARS-COV-2 RdRp with 
double-stranded template-primer RNA and Remdesivir [12] to analyze the binding patterns of the 
drug. The structure reveals that the double stranded RNA is inserted into RdRp’s central channel 
and the active triphosphate form of Remdesivir is covalently bound to the primer strand at the first 
replicated base to terminate the chain elongation. The prodrug form of Remdesivir does not have 
any inhibitory effect on the polymerization activity of the purified enzyme [12]. Our analysis reveals 
that fastest normal modes (corresponding to kinetically active residues) delineate the central 
channel (Figure 3) and that enzymatically important residues K500, S501, K545 and R555 are all 
recognized by the SAGNM algorithm using the fastest normal mode. With the first two modes the 
residue D761 of the catalytic center is also emphasized (out of residues 759-761 that form the 
catalytic center). Residues K545 and R555 are important because stabilize incoming nucleotide 
in the correct position for catalysis. The crystal structure shows that NSP12 does not have any 
contacts with base pairs of RNA emphasizing RdRp’s sequence-agnostic polymerization ability 
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[12]. This is in concordance with our analysis which emphasizes stable, kinetically active residues 
as ket segments of the enzyme’s central channel. 
 
We also performed a comparative analysis of Hepatitis C virus (HCV) RdRp (pdb id 4wtg, chain 
A) and Covid-19 RdRp (pdb id 6m71, chain A). We followed the steps of Y. Gao and collaborators 
[27] and analyzed the binding residues prediction of HCV RNA directed RNA polymerase (pdb id 
4wtg) to sofosbuvir and compared them to binding residues prediction s in Covid-19 RNA directed 
RNA polymerase  (pdb id 6m71). The binding residues in HCV are buried deep inside the 
polymerase and they are generally kinetically active (Figure S1a), but they are not explicitly 
hydrophobic (Fig. S1b-c). The structural alignment of HCV and Covid-19 RdRp (Figure S1d) 
shows that they share the structure of the binding pocket, but also reveals significant differences. 
The analysis of the kinetically active residues in Covid-19 RdRp reveals that catalytic core is 
bounded by the kinetically active residues, although the overall distribution of residues is slightly 
different in comparison to HCV (Figure S1e). That analysis of SARS-COV-2 with Remdesivir (pdb 
id 7bv2) and HCV with sofosbuvir (pdb id 4wtg) suggests that the interior of the viral RdRp is an 
attractive binding spot for small compounds in general.  
 
We also analyzed binding patterns of NSP7 and NSP8 for NSP12. Figure S2 shows that NSP7 
and NSP8 also seek patches with kinetically active residues on the surface of NSP12. However, 
they are also in contact with kinetically less active areas. This should be analyze in the light of 
fact that SARS-COV-2 RdRp (NSP12) cannot perform its function without NSP7 and NSP8. The 
distribution of highly active and less active residues may be important for the overall stability of 
NSP12 and act as thermodynamic engine giving a regular translational rhythm  
 
The drug α-difluoromethylornithine (Eflornithine) prohibits binding of the natural non-coded amino 
acid ornithine to the active site on the surface of Trypanosoma brucei ornithine decarboxylase 
(ODC, pdb id 1njj). Therefore, binding of this drug should follow the binding patterns of ornithine. 
Figure S3. shows that SAGNM algorithm accurately detects binding sites for both ornithine and 
G418 (Geneticin), an aminoglycoside antibiotic. In contrary to chloroquine both compounds bind 
preferably to hydrophilic sites on the surface of ODC. If applied to treat Covid-19, the drug 
Eflornithine should bind to similar sites on the surface of Covid-19 proteins (hydrophobic and 
kinetically active). 
 
The analysis of the contact patterns between the ACE2 receptor and the spike glycoprotein’s 
receptor binding domain (RBD) (Figure 4) in both SARS (pdb id 6cs2) and Covid-19 (pdb id 6m0j) 
reveals a significant difference in the distribution of residues important for binding between the 
two viral proteins. SARS-RBD has a smaller number of kinetically active and adjoining residues 
[15] in direct contact with ACE2 (Figure 4a-c) than Covid-19-RBD (Figure 4d-f). The kinetically 
active and adjoining residues n Covid-19 are directly oriented and are in contact with the active 
residues in ACE2, while in SARS such residues are mostly perpendicular to the interfacial plane 
(compare the distributions of C-alpha atoms in Figs. 4a and 4d). That should make the binding 
affinity between the Covid-19-RBD and ACE2 receptor stronger than between the SARS-RBD 
and ACE2 receptor. In both cases the predicted residues are recognized via the fastest vibrational 
mode.  
 
The analysis of kinetically active and adjoining residues in the SARS monomer (Figure S4) 
reveals that they are attractive binding spots for glycans that form the glycan shield, which was 
already suggested to assist in immune evasion similarly to the HIV-1 envelope trimer [28]. The 
kinetically active residues recognized by the SAGNM algorithm can be, therefore, used as target 
areas for drugs aimed at removing/disrupting the viral glycan shield. Those residues are not 
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particularly hydrophobic and should be targeted by drugs that bind to hydrophilic patches, and 
electrostatically complementary. 
 
 
Conclusion 
 
Covid-19 is the first severe global pandemic caused by a coronavirus, and there are no 
guarantees that it will be the last. Therefore, we need not only to develop an effective and efficient 
treatment for the current pandemic, but we also have to design a set of protocols to address all 
future, similar pandemics. In this manuscript we presented our strategy to recognize drug binding 
residues in viral proteins. We analyzed four currently approved drugs (chloroquine, Ivermectin, 
Remdesivir, and Eflornithine). Our results indicate that small, drug like compounds preferentially 
bind to kinetically active and adjoining residues. Some of the drugs seek active patches on the 
protein surfaces that are mostly hydrophobic (Chloroquine, Ivermectin), while other prefer 
hydrophilic patches (Remdesivir, Sofosbuvir, Eflornithine). That may imply that in designing drug 
cocktails for viruses, drugs binding to hydrophobic and hydrophilic patches should be combined 
to avoid conflicts and reduce toxicity and side effects  
 
In our analysis we used both viral-parasitic, as well as human proteins. The analysis shows that 
kinetically active residues exist in both human and non-human proteins/enzymes and that drugs 
bind indiscriminately to them regardless of their origin. This should  
 
This information may also help in accessing drug toxicity. Binding spots can be predicted with our 
SAGNM approach and accessed with other bioinformatics tools for shape complementarity, 
binding affinity, and other properties as well. 
 
The procedure we developed is fast and effective, and can analyze a protein much faster than 
computationally demanding molecular dynamics simulations. The only requirement is the protein 
structure. Its advantage is not in its efficiency, but also in its ability to suggest general binding 
patterns between drugs/small peptides and proteins. It can be used to filter binding areas on 
protein surfaces and thus facilitate preclinical stages in drug design. 
 
Acknowledgement: The author would like to thank G.A. Mansoori for his encouragements to 
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Figures 
 
 
 
Figure 1. Chloroquine and its target proteins. Images on the left depict chloroquine bound to Saposin B 
(pdb id 1cet). Images on the right depict chloroquine bound to cofactor binding site of Plasmodium 
Falciparum Lactate Dehydrogenase (pdb id 4v2o). 
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Figure 2. Ivermectin and its target protein, Human glycine receptor Alpha-3 (pdb id 5vdh). 
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Figure 3. Remdesivir bound to primer RNA inside the central channel of SARS-COV-2 RNA dependent 
RNA polymerase (RdRp), NSP12) (pdb id 7bv2 described in [12]). The dashed lines represent missing 
segments. 
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Figure 4. SARS spike glycoprotein chain B RBD and ACE2 receptor (pdb id 6cs2) in comparison to Covid-
19 spike glycoprotein chain A RBD and ACE2 receptor (pdb id 6m0j). In a) and d) spike glycoprotein’s 
predictions are shows through C-alpha atoms only. In b, c, e and f predictions are shown through all atoms. 
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Supplementary material 
 
Drug Indication 
Dosage in 
individuals 
aged ≥ 12 
years 
Effectiveness 
Side 
effects  
Precautions in patients with 
complications 
Cardio-
Pulmonary 
Renal Hepatic Retinal 
Chloroquine 
Treatment 
Prevention 
500-600 
mg weekly 
Malaria, 
Amebiasis, 
Porphyria 
Cutanea Tarda 
Serious Yes Yes Yes Yes 
Ivermectin 
Treatment 
Prevention 
3-15 mg 
once 
Parasitic 
infestations 
Mild-
Serious 
No Yes Yes No 
Remdesivir Treatment 
100-200 
mg daily 
Ebola, Marburg 
virus diseases 
Mild No Yes No No 
α-Difluoromethylornithine Treatment 
300-400 
mg/kg/day, 
cream 
Trypanosomiasis, 
reduction of facial 
hair in women 
Mild-
Serious 
No No Yes No 
Table S1. Comparison of existing drugs currently being tested for the antiviral treatment and prevention of 
Covid-19 through drug repurposing. 
Methods and Materials 
Our aim was to analyze presently available structures of COVID-19 proteins and predict their 
binding patterns to the above described four drugs as well as to the human ACE2 receptor. To 
predict binding residues in protein we applied our Self Adjustable interpretation of Gaussian 
Network Model (SAGNM) [15]. The structure alignment, visualization and analyses were 
performed with programs Chimera [13] and VMD [14]. Missing segments in some proteins 
structures were modeled with the program Modeller [29].  
 
We focused our study on pdb structures with the listed drugs present as ligands. For chloroquine 
we analyzed 2 structures (saposin pdb id 1cet, and 4v2o).  For Ivermection we analyzed the 
binding pattern of the drug to the Human glycine receptor (pdb id 4wtg). For Remdesivir we 
analyzed its binding patterns in the recently released structure [12] (pdb id 7bv2). We also 
performed the analysis of binding pattern of drug Sofosbuvir to the hepatitis C virus (HCV) RdRp 
(pdb id 4wtg) and compared them to the Covid-19 RdRp predictions (pdb id 6m71). Sofosbuvir 
was already analyzed in light of similarities between HCV and SARS-COV-2 RdRp and similarities 
between Remdesivir’s and Sofosbuvir’s [27]. For α-Difluoromethylornithine we analyzed a 
structure of Trypanosoma brucei ornithine decarboxylase (ODC) with D-ornithine bound to it (pdb 
id 1njj). α-Difluoromethylornithine binds to the active site of ODC and inhibits ornithine binding to 
it. We also analyzed the spike glycoprotein from SARS with S230 human neutralizing antibody 
(pdb id 6nb6) and Covid-19 spike glycoprotein (pdb id 6vsb). 
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Supplementary material figures 
 
 
 
Figure S1. Comparative analysis of HCV (pdb id 4wtg, chain A, figures of the left) and Covid-19 RNA 
directed RNA polymerase (pdb id 6m71, chain A, figures on the right). HCV RNA directed RNA polymerase 
has sofosbuvir bound to it. With Covid-19 RNA polymerase sofosbuvir’s position corresponds to the position 
it has when bound to HCV RNA polymerase. 
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Figure S2. Covid-19 RNA directed RNA polymerase with cofactors NSP7 and NSP8 (pdb id 6m71). The 
algorithm predictions are yellow. The green sticks represent missing segments. 
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Figure S3. D-ornithine and its target protein Trypanosoma brucei ornithine decarboxylase (pdb id 1njj). 
Lower figures depict ornithine decarboxylase monomer. 
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Figure S4. SARS-Cov spike glycoprotein (Chain B, pdb id 6nb6) and glycans (NAG, BMA, MAN) linked to 
it. The algorithm predictions are yellow. The predictions accurately predict binding spots for glycans. They 
can be used as target areas for drugs aimed at removing/disrupting the virus glycan shield. Cyan bars 
(Figure 6a) represent missing segments. 
 
 
 
 
